These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26938202)

  • 1. Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis.
    Yu H; Karunakaran KP; Jiang X; Brunham RC
    Expert Rev Vaccines; 2016 Aug; 15(8):977-88. PubMed ID: 26938202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Chlamydia trachomatis Vaccinology.
    de la Maza LM; Zhong G; Brunham RC
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28228394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
    Hadad R; Marks E; Kalbina I; Schön K; Unemo M; Lycke N; Strid Å; Andersson S
    APMIS; 2016 Dec; 124(12):1078-1086. PubMed ID: 27859689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis.
    Eko FO; Lubitz W; McMillan L; Ramey K; Moore TT; Ananaba GA; Lyn D; Black CM; Igietseme JU
    Vaccine; 2003 Apr; 21(15):1694-703. PubMed ID: 12639492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant expression of Chlamydia trachomatis major outer membrane protein in E. Coli outer membrane as a substrate for vaccine research.
    Wen Z; Boddicker MA; Kaufhold RM; Khandelwal P; Durr E; Qiu P; Lucas BJ; Nahas DD; Cook JC; Touch S; Skinner JM; Espeseth AS; Przysiecki CT; Zhang L
    BMC Microbiol; 2016 Jul; 16(1):165. PubMed ID: 27464881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a Chlamydia trachomatis vaccine: how close are we?
    Cochrane M; Armitage CW; O'Meara CP; Beagley KW
    Future Microbiol; 2010 Dec; 5(12):1833-56. PubMed ID: 21155665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ⁺ CMI responses protects against a genital infection in minipigs.
    Bøje S; Olsen AW; Erneholm K; Agerholm JS; Jungersen G; Andersen P; Follmann F
    Immunol Cell Biol; 2016 Feb; 94(2):185-95. PubMed ID: 26268662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for the rational design of a Chlamydia vaccine.
    Liang S; Bulir D; Kaushic C; Mahony J
    Hum Vaccin Immunother; 2017 Apr; 13(4):831-835. PubMed ID: 27835064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlamydia trachomatis control requires a vaccine.
    Brunham RC; Rappuoli R
    Vaccine; 2013 Apr; 31(15):1892-7. PubMed ID: 23375977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity, immunopathology, and human vaccine development against sexually transmitted Chlamydia trachomatis.
    Rey-Ladino J; Ross AG; Cripps AW
    Hum Vaccin Immunother; 2014; 10(9):2664-73. PubMed ID: 25483666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential for vaccine development against chlamydial infection and disease.
    Brunham RC; Zhang DJ; Yang X; McClarty GM
    J Infect Dis; 2000 Jun; 181 Suppl 3():S538-43. PubMed ID: 10839755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Th1/Th17 T cell Tissue-Resident Immunity Increases Protection, But Is Not Required in a Vaccine Strategy Against Genital Infection With
    Nguyen NDNT; Guleed S; Olsen AW; Follmann F; Christensen JP; Dietrich J
    Front Immunol; 2021; 12():790463. PubMed ID: 34925371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Chlamydia trachomatis vaccine for urogenital infections: novel tools and new strategies point to bright future prospects.
    Hafner LM; Timms P
    Expert Rev Vaccines; 2018 Jan; 17(1):57-69. PubMed ID: 29264970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mucosal immune response to Chlamydia trachomatis infection of the reproductive tract in women.
    Agrawal T; Vats V; Salhan S; Mittal A
    J Reprod Immunol; 2009 Dec; 83(1-2):173-8. PubMed ID: 19896206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis.
    Frietze KM; Lijek R; Chackerian B
    Expert Rev Vaccines; 2018 Nov; 17(11):959-966. PubMed ID: 30300019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chlamydial genomics and vaccine antigen discovery.
    Stephens RS
    J Infect Dis; 2000 Jun; 181 Suppl 3():S521-3. PubMed ID: 10839752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus core antigen as a carrier for Chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital chlamydial infection.
    Jiang P; Du W; Xiong Y; Lv Y; Feng J; Zhu S; Xue X; Chen S; Zhang L
    Oncotarget; 2015 Dec; 6(41):43281-92. PubMed ID: 26657117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a multi-epitope protein vaccine against herpes simplex virus, human papillomavirus and Chlamydia trachomatis as the main causes of sexually transmitted diseases.
    Dorosti H; Eskandari S; Zarei M; Nezafat N; Ghasemi Y
    Infect Genet Evol; 2021 Dec; 96():105136. PubMed ID: 34775078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development status and future prospects for a vaccine against Chlamydia trachomatis infection.
    Hafner LM; Wilson DP; Timms P
    Vaccine; 2014 Mar; 32(14):1563-71. PubMed ID: 23973245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
    He Q; Martinez-Sobrido L; Eko FO; Palese P; Garcia-Sastre A; Lyn D; Okenu D; Bandea C; Ananaba GA; Black CM; Igietseme JU
    Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.